今日具体限售解禁股情况如下： 智通财经APP获悉，9月29日共有25家上市公司的限售股解禁，解禁总市值约248.18亿元。 | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 泸州老窖 | 000568 | 股权激励限售流通 | 10.27万 | | 华东医药 | 000963 | 股权激励限售流通 | 21.5万 | | 太原重工 | 600169 | 股权激励限售流通 | 1165.02万 | | 金发科技 | 600143 | 股权激励限售流通 | 740.6万 | | 国泰君安 | 601211 | 股权激励限售流通 | 324.95万 | | 广联达 | 002410 | 股权激励限售流通 | 323.34万 | | 宁波港 | 601018 | 增发A股法人配售上市 | 36.47亿 | | 中金环境 | 300145 | 股权激励限售流通 | 852.07万 | | 可立克 | 002782 | 股权激励限售流通 | 76.8万 | | 英杰电气 | 300820 | 股权激励限售流通 | 6.25万 | | 老百姓 | 6038 ...

Group 1 - The core viewpoint of the news is that Rendu Biotech has shown fluctuations in its stock performance, with a year-to-date increase of 34.89% and a recent drop of 10.11% over the past 20 days [1] - As of June 30, the number of shareholders for Rendu Biotech increased by 7.54% to 3,495, while the average circulating shares per person decreased by 7.01% to 9,032 shares [2] - The company reported a revenue of 81.24 million yuan for the first half of 2025, representing a year-on-year decrease of 6.27%, and a net profit of 2.04 million yuan, down 52.94% year-on-year [2] Group 2 - Rendu Biotech has a market capitalization of 1.93 billion yuan and its stock price was 48.09 yuan per share as of September 25 [1] - The company's main business revenue composition includes 90.04% from reagent business, 8.49% from instrument business, and 1.47% from testing services [1] - Since its A-share listing, Rendu Biotech has distributed a total of 20.58 million yuan in dividends [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 除此之外，本次上市流通的限售股形成后至今，公司未发生因利润分配、公积金转增导致股本数量变化 的情况。 三、本次上市流通的限售股的有关承诺 ● 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为8,431,604股。 本次股票上市流通总数为8,431,604股。 ● 本次股票上市流通日期为2025年9月30日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会于2022年2月15日出具的《关于同意上海仁度生物科技股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕332号）同意，公司获准向社会公开发行人民币普通股 （A股）10,000,000股，并于2022年3月30日在上海证券交易所科创板挂牌上市。公司首次公开发行A股 前总股本为30,000,000股，首次公开发行A股后总股本为40,000,000股，其中有限售条件流通股为 31,818,377股，占总股本比例为79.55%，无限 ...

证券日报网讯 9月22日晚间，仁度生物发布公告称，本次股票上市类型为首发限售股份；股票认购方式 为网下，上市股数为8，431，604股。本次股票上市流通总数为8，431，604股。本次股票上市流通日期 为2025年9月30日。 （编辑 楚丽君） ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁 度生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在 科创板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易 所科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》等有关法律法规和规范性文件的要求，对仁度生物首次公开发行部分限售股解禁上 市流通事宜进行了核查，发表核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会于 2022 年 2 月 15 日出具的《关于同意上海仁度生物科 技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332 号）同意，公 司获准向社会公开发行人民币普通股（A 股）10,000,000 股，并于 2022 年 3 月 30 日在 上海证券交易所科创板挂牌上市。公司首次公开发行 A 股前总股本为 30,000,000 股， 首次公开发行 A 股后总股本为 40,000,000 股，其中有限售条件流通股为 ...

一、本次上市流通的限售股类型 经中国证券监督管理委员会于2022年2月15日出具的《关于同意上海仁度生物 科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕332号）同 意，公司获准向社会公开发行人民币普通股（A股）10,000,000股，并于2022年3 月30日在上海证券交易所科创板挂牌上市。公司首次公开发行A股前总股本为 30,000,000股，首次公开发行A股后总股本为40,000,000股，其中有限售条件流通股 为31,818,377股，占总股本比例为79.55%，无限售条件流通股为8,181,623股，占总 股本比例为20.45%。 本次上市流通的限售股为公司首次公开发行前股东持有的部分限售股，涉及 限售股股东数量为2名，限售期限为自公司股票上市之日起42个月，该部分限售股 股东对应的股份总数为8,431,604股，占公司股本总数的21.04%。现锁定期即将届 满，上述限售股将于2025年9月30日起上市流通。 证券代码：688193 证券简称：仁度生物 公告编号：2025-040 上海仁度生物科技股份有限公司 关于公司首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保 ...

中国国际金融股份有限公司 关于上海仁度生物科技股份有限公司 2025 年半年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁度 生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，负责仁度生物上市后的持续督导工作，并出具本持续督导半年度跟踪报 告，具体情况如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体 的持续督导工作制定相应的工作计划 | 保荐机构已建立并有效执行了持 | | | | 续督导制度，并制定了相应的工 | | | | 作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐机构已与公司签订《保荐协 | | | 与上市公司或相关当事人签署持续督导协议，明确双 | 议》，该协议明确了双方在持续 | | | 方在持续督导期间的权利义务 ...

Core Insights - The company has achieved a breakthrough in research and development with the successful creation of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT," which surpasses existing digital PCR technology in sensitivity, ease of use, and speed of detection [2] - The platform opens new pathways for precise RNA quantification detection and is expected to be applied in areas such as early cancer screening, infectious disease detection, and personalized medicine [2] - The company has initiated the development of RNA digital precision quantification detection products, focusing on urinary system tumor screening products for prostate cancer and bladder cancer [2] - The company is actively pursuing intellectual property protection around its core technology, with several domestic and international invention patents applied for, some of which have already been granted [2] - Additionally, the company's self-developed Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents have successfully passed EU regulatory agency review and obtained IVDRCE certification, facilitating future international collaborations and expansion of overseas sales networks [2]

Core Insights - Shanghai Rendu Biotechnology Co., Ltd. has released a semi-annual evaluation report on its "Quality Improvement and Efficiency Enhancement Return" action plan, highlighting the successful development of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT" [1] - The new platform demonstrates significant advantages in detection sensitivity, operational convenience, and detection speed compared to traditional digital PCR technology, offering a more efficient and precise RNA detection solution with broad application potential [1] - Rendu Biotechnology is advancing the application of the Digital SAT platform in urinary system tumor screening, particularly for prostate and bladder cancer urine tests, with notable research progress [1] - The company aims to leverage its technological advantages to penetrate the tumor screening field amid the ongoing global development of precision medicine and early screening technologies [1]

Core Viewpoint - RenDu Bio (688193) reported a decline in revenue and net profit for the first half of 2025, but is positioning itself for long-term growth through technological innovation and international expansion [1][2][3] Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% compared to the previous year [1] Product Development and Innovation - RenDu Bio focused on building new technology platforms and developing new product lines, successfully creating the "Digital SAT + Automatic Supporting Equipment DigiNAT" platform - This platform offers significant advantages over traditional digital PCR technology, including reduced DNA background interference and improved detection speed - The company is developing RNA digital quantitative detection products, particularly for cancer screening and diagnosis, with progress in prostate and bladder cancer tests [2] Market Opportunities - The global liquid biopsy market is expected to maintain a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments - The rising demand for early screening and diagnosis of high-incidence tumors like prostate and bladder cancer presents a significant opportunity for the company [2] International Expansion - RenDu Bio has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India - The company has also secured IVDR CE certification for its Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents, enhancing its ability to enter the EU market [3] Regulatory and Competitive Landscape - The IVDR certification signifies the company's strong capabilities in product development and compliance, which is crucial in the highly regulated EU market - The successful certification of key products highlights the company's systematic advantages in research, clinical translation, and regulatory compliance, laying a solid foundation for future international registrations [3]